Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.

Xiao HanXiaoyong TangHui ZhuDongyuan ZhuXiqin ZhangXiangjiao MengYing HuaZhongtang WangYan ZhangWei HuangLinlin WangShuanghu YuanPinliang ZhangHeyi GongYulan SunYingjie ZhangZengjun LiuXiaomeng DongFei GaiZhan HuangChangbin ZhuJun GuoZhehai Wang

Published in: Journal for immunotherapy of cancer (2023)

ctDNA status and ctDNA mutation clearance putatively serve as predictive biomarkers for sintilimab combined with docetaxel chemotherapy in pretreated advanced NSCLC patients.

Keyphrases

circulating tumor
cell free
circulating tumor cells
small cell lung cancer
end stage renal disease
locally advanced
ejection fraction
newly diagnosed
advanced non small cell lung cancer
chronic kidney disease
peritoneal dialysis
patient reported outcomes
rectal cancer
radiation therapy